mTOR inhibition also appears to be effective when combined with conventional chemotherapy in ALL [85,96] and with drugs targeting the epigenetic machinery, inducing apoptosis, as well as increased mitochondria sensitivity to initiate cell death [97] and inhibiting BCL2 protein family leading to increased cytotoxicity [98]. Here, BCL2 is linked to acute lymphoblastic leukemia.